RFCA
SRNE

R&F Capital Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

R&F Capital Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$51K Buy
+12,878
New +$64.6K 0.01% 647

Other funds holding SRNE

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

R&F Capital Advisors's SRNE Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Sorrento Therapeutics, Inc. (SRNE) in Q1 2017: 12,878 shares worth $51K. The stake represents 0.01% of the portfolio and ranks #647 among its holdings.

64 funds tracked by Wall St. Rank hold SRNE as of Q1 2017.

  • R&F Capital Advisors held 12,878 shares of Sorrento Therapeutics, Inc. worth $51K as of Q1 2017.
  • Sorrento Therapeutics, Inc. was a new R&F Capital Advisors position in Q1 2017.
  • Sorrento Therapeutics, Inc. made up 0.01% of R&F Capital Advisors's portfolio in Q1 2017, its #647 holding.
  • 64 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.